HLA-C and small cell lung carcinoma: Consistently, highly heterozygous MHC sites were correlated with significantly improved OS after ICI treatment (P = 0.003; HR, 2.03) (74), demonstrating the potential of MHC expression as a predictive biomarker for ICI treatment in SCLC.